Ensign Peak Advisors’s NewAmsterdam Pharma NAMS Stock Holding History
Bought
Maintained
Sold
Other funds holding NAMS
DFO
Ensign Peak Advisors's NAMS Position: Q3 2026 in Review
Ensign Peak Advisors sold out of NewAmsterdam Pharma (NAMS) in Q3 2026, closing a stake of 212,423 shares — an estimated $7.2M sold.
Ensign Peak Advisors first reported a position in NAMS in Q4 2022 and held it in 11 quarters. The position peaked at $19.3M in Q4 2025. 183 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.
- Ensign Peak Advisors reported no remaining NewAmsterdam Pharma position as of Q3 2026 after selling out during the quarter.
- Ensign Peak Advisors sold 212,423 NewAmsterdam Pharma shares in Q3 2026, an estimated $7.2M.
- Ensign Peak Advisors first reported a position in NewAmsterdam Pharma in Q4 2022 and held it in 11 quarters.
- Ensign Peak Advisors's NewAmsterdam Pharma position peaked at $19.3M in Q4 2025.
- 183 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.